| Name | Title | Contact Details |
|---|
LED Dental traces its roots back to the mid-1990s, when company founder Peter Whitehead began performing oral cancer research in conjunction with the British Columbia Cancer Agency (BCCA). In 2000, Peter and a fellow BCCA researcher were awarded patents for groundbreaking technologies they developed for detecting oral cancer. Peter ultimately formed LED Medical Diagnostics Inc. and it operating subsidiary, LED Dental, to focus on the advancement of these technologies. LED Dental, in concert with the BCCA, ultimately co-developed the patented VELscope® Vx Enhanced Oral Assessment System, a tissue fluorescence visualization technology that received FDA and Health Canada clearance in 2006. Since then, there have been more than 12,000 VELscope Vx systems sold globally, and they have been used to perform more than 25 million oral examinations worldwide. In early 2014, LED Dental entered the dental imaging market in response to the explosive growth in dental CAD/CAM and the shift away from film-based systems to faster, more efficient and higher quality digital imaging solutions. We serve a previously unmet market demand for "open architecture" digital imaging technologies and we are rapidly growing a comprehensive portfolio of state-of-the-art offerings to meet this demand. Guiding our growth is a management team comprised some of the best minds from both the clinical and business sides of the dental industry. Drawing upon their decades of collective experience, they are identifying target technologies and product lines for our portfolio; building and managing our operations and sales teams; and developing a streamlined chain of communication that enables us to listen closely and serve the needs of our customers - and, in turn, enabling these clients to best serve their patients.
Health Care System Consultants, Inc is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rees Scientific Corp. is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid equips physicians with critical information designed to enable precision medicine. Elucid is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts (“Virtual Transcriptomics”). This unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs. The Elucid software is available for commercial use in the U.S. and Europe
GDM's VACS software provides capture capabilities and collaborative tools using typically un-captured but critical visual information between patients, clinicians and medical specialists. VACS helps solve the problems today’s clinicians face relating to increased patient flow, less time available and increased demand for better outcomes. The VACS platform, which includes proprietary management software, digital capture/streaming and mobile applications, provides a new level of “rich media” capture, access, interaction and use of images, video, audio and other data elements. Management is currently focused on expanding the VACS platform internationally, to increase clinical efficiency and bridge the visual information gap in today’s growing clinical collaboration processes